Standard BioTools Inc.: updates and filings

LABNASDAQHealthcare · Pharmaceutical Preparations

Price

$0.62

November 16, 2026Market cap $242M

What Ploutos Investor adds for Standard BioTools

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 79 daysAround Feb 4, 2027 · for Q4 2026

last Aug 5, 2026next Feb 4, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 16, 2026 latest annualNov 3, 2026 latest quarterly
  • Nov 16, 2026Filing
    Form425
  • Nov 16, 2026Other material events
    Form8-K
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 3, 2026Filing
    Form425
  • Nov 3, 2026Regulation FD disclosure
    Form8-K
  • Oct 21, 2026Filing
    FormEFFECT
  • Oct 21, 2026Filing (amendment)
    FormS-4/A
  • Oct 9, 2026Filing (amendment)
    FormS-4/A
  • Oct 5, 2026Filing
    Form425
  • Oct 5, 2026Regulation FD disclosure
    Form8-K
  • Sep 30, 2026Filing
    Form425
  • Sep 30, 2026Material agreement entered, material agreement ended, Regulation FD disclosure
    Form8-K
  • Sep 9, 2026Filing (amendment)
    FormS-4/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 5, 2026Shares registered for employees
    FormS-8
  • Aug 5, 2026Shares registered for employees
    FormS-8
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Jul 30, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 29, 2026Filing
    Form425
  • Jul 29, 2026Financial statements and exhibits (amendment)
    Form8-K/A
  • Jul 28, 2026Filing
    Form425
  • Jul 28, 2026Filing
    Form425

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Jan 18, 2002: every report, 8-K, meeting and letter. Of its other filings (693 in all), the newest.

The full analysis

What do Standard BioTools's filings show?

The filings are where every one of Standard BioTools's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.